CT-95 in Advanced Cancers Associated With Mesothelin Expression
Recruiting
Phase 1
Interventional Study
Mesothelin-Expressing Tumors
Epithelial Ovarian Cancer
Malignant Pleural Mesothelioma, Advanced
Malignant Peritoneal Mesothelioma, Advanced
Pancreatic Adenocarcinoma Advanced or Metastatic
Lung Adenocarcinoma Metastatic
Cholangiocarcinoma Advanced
Cholangiocarcinoma Non-resectable
Mesothelin-expressing Advanced Cancers
Mesothelin-positive Advanced Malignant Solid Tumors
Colorectal Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 70 (estimated)
- Sponsor
- Context Therapeutics Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* ECOG 0 or 1
* Subjects with evaluable disease per RECIST 1.1 or mRECIST
* Subjects with adequate organ function.
* Subjects with advanced cancers associated with mesothelin expression
Exclusion Criteria:
* Uncontrolled significant active infection or any medical or other con…
Contacts